drugset / Trial / NCT02506790

Neoadjuvant Toremifene With Melatonin or Metformin in Locally Advanced Breast Cancer

NCT02506790

RandomizedParallel-groupOpen-labelTreatment

Summary

This study evaluates the addition melatonin and metformin to toremifene in the treatment of locally advanced breast cancer. Third of patients will receive toremifene, other third will receive combination of melatonin and toremifene and other patients will receive combination of metformin and toremifene.

Timeline

Start
2015-07
Primary completion
2020-08
Completion
2022-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Melatonin Small molecule 3 mg
Subject Metformin Small molecule 850 mg
Background Toremifene Small molecule 60 mg

Indications